Search research articles
Contact Us
Filters
Showing results (131-140 of 149) with videos related to
Page
of 15
Sort By:
Gut
|
September 1, 1987
Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs
D B Jones, C W Howden, D W Burget, et al.
European Journal of Clinical Pharmacology
|
January 1, 1987
The effects of omeprazole on endocrine function in man
A J MacGilchrist, C W Howden, C J Kenyon, et al.
Alimentary Pharmacology & Therapeutics
|
April 1, 2006
Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h
C W Howden, D C Metz, B Hunt, et al.
Archives of Internal Medicine
|
July 24, 1995
The rationale for continuous maintenance treatment of reflux esophagitis
C W Howden, D O Castell, S Cohen, et al.
Alimentary Pharmacology & Therapeutics
|
February 13, 2009
Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis
D C Metz, C W Howden, M C Perez, et al.
The American Journal of Gastroenterology
|
August 19, 2000
Survey of internal medicine residents' use of the fecal occult blood test and their understanding of colorectal cancer screening and surveillance
V K Sharma, F A Corder, J P Raufman, et al.
Alimentary Pharmacology & Therapeutics
|
February 17, 2006
Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey
W D Chey, S Eswaren, C W Howden, et al.
Alimentary Pharmacology & Therapeutics
|
August 1, 1987
Marked suppression of stimulated gastric acid and pepsin secretion by enisoprost, a new PGE1 analogue
C W Howden, D W Burget, C Silletti, et al.
Alimentary Pharmacology & Therapeutics
|
November 6, 2004
Review article: oesophageal complications and consequences of persistent gastro-oesophageal reflux disease
J Pisegna, G Holtmann, C W Howden, et al.
Gut
|
December 1, 1991
Increased intestinal permeability in ankylosing spondylitis--primary lesion or drug effect?
A J Morris, C W Howden, C Robertson, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 149) with videos related to
Sort By:
Page
of 15
Gut
|
September 1, 1987
Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs
D B Jones, C W Howden, D W Burget, et al.
European Journal of Clinical Pharmacology
|
January 1, 1987
The effects of omeprazole on endocrine function in man
A J MacGilchrist, C W Howden, C J Kenyon, et al.
Alimentary Pharmacology & Therapeutics
|
April 1, 2006
Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h
C W Howden, D C Metz, B Hunt, et al.
Archives of Internal Medicine
|
July 24, 1995
The rationale for continuous maintenance treatment of reflux esophagitis
C W Howden, D O Castell, S Cohen, et al.
Alimentary Pharmacology & Therapeutics
|
February 13, 2009
Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis
D C Metz, C W Howden, M C Perez, et al.
The American Journal of Gastroenterology
|
August 19, 2000
Survey of internal medicine residents' use of the fecal occult blood test and their understanding of colorectal cancer screening and surveillance
V K Sharma, F A Corder, J P Raufman, et al.
Alimentary Pharmacology & Therapeutics
|
February 17, 2006
Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey
W D Chey, S Eswaren, C W Howden, et al.
Alimentary Pharmacology & Therapeutics
|
August 1, 1987
Marked suppression of stimulated gastric acid and pepsin secretion by enisoprost, a new PGE1 analogue
C W Howden, D W Burget, C Silletti, et al.
Alimentary Pharmacology & Therapeutics
|
November 6, 2004
Review article: oesophageal complications and consequences of persistent gastro-oesophageal reflux disease
J Pisegna, G Holtmann, C W Howden, et al.
Gut
|
December 1, 1991
Increased intestinal permeability in ankylosing spondylitis--primary lesion or drug effect?
A J Morris, C W Howden, C Robertson, et al.
Page
of 15